AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

PreveCeutical Medical Inc.

$0.01 -$0.00 (-18.08%)
OTC · 14 Sep 2026 19:09 UTC
Previous Close
$0.01
Day Range
$0.01$0.01
Year Range
$0$0.04
Market Cap
8.67M
AVG Volume
29.19K
Trailing/Forward PE
-12.5/-
PEG ratio
-0.11
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (CAD) · TTM
00.250.50.75124 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRVCF Revenue (CAD) · TTM by quarter
PeriodRevenue (CAD) · TTM
26 Q20
26 Q10
25 Q40
25 Q30
25 Q20
25 Q10
24 Q40
24 Q30
24 Q20
24 Q10
Net Income (CAD) · TTM
-4M-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRVCF Net Income (CAD) · TTM by quarter
PeriodNet Income (CAD) · TTM
26 Q2-689.26K
26 Q1-1.4M
25 Q4-1.63M
25 Q3-3.08M
25 Q2-2.6M
25 Q1-1.7M
24 Q4-1.17M
24 Q3-1.36M
24 Q2-1.26M
24 Q1-1.13M
Operating Income (CAD) · TTM
-4M-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRVCF Operating Income (CAD) · TTM by quarter
PeriodOperating Income (CAD) · TTM
26 Q2-2.3M
26 Q1-3.1M
25 Q4-3.37M
25 Q3-2.8M
25 Q2-2.27M
25 Q1-1.34M
24 Q4-811.98K
24 Q3-1.01M
24 Q2-923.47K
24 Q1-810.49K
EBITDA (CAD) · TTM
-4M-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRVCF EBITDA (CAD) · TTM by quarter
PeriodEBITDA (CAD) · TTM
26 Q2-2.26M
26 Q1-3.04M
25 Q4-3.34M
25 Q3-2.78M
25 Q2-2.26M
25 Q1-1.36M
24 Q4-837.64K
24 Q3-1.02M
24 Q2-927.9K
24 Q1-801.71K
Cash Flows (CAD) · TTM
-2M-1.5M-1M-500K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRVCF Cash Flows (CAD) · TTM by quarter
PeriodCash Flows (CAD) · TTM
26 Q2-1.6M
26 Q1-1.89M
25 Q4-1.78M
25 Q3-1.31M
25 Q2-903.56K
25 Q1-531.12K
24 Q4-428.49K
24 Q3-399.04K
24 Q2-335.61K
24 Q1-257.43K
EPS (CAD) · TTM
-0.01-0-0024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRVCF EPS (CAD) · TTM by quarter
PeriodEPS (CAD) · TTM
26 Q2-0
26 Q1-0
25 Q4-0
25 Q3-0.01
25 Q2-0
25 Q1-0
24 Q4-0
24 Q3-0
24 Q2-0
24 Q1-0
Expenses (CAD) · TTM
-1M01M2M3M4MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRVCF Expenses (CAD) · TTM by quarter
PeriodExpenses (CAD) · TTM
26 Q22.16M
26 Q12.95M
25 Q43.29M
25 Q32.87M
25 Q22.32M
25 Q11.4M
24 Q4806.96K
24 Q3943.9K
24 Q2856.06K
24 Q1725.18K
Shares Outstanding (CAD) · TTM
-800K-600K-400K-200K0Buybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRVCF Shares Outstanding (CAD) · TTM by quarter
PeriodShares Outstanding (CAD) · TTM
26 Q2-154.66K
26 Q1-639.54K
25 Q4-728.97K
25 Q3-783.75K
25 Q2-739.06K
25 Q1-210.04K
24 Q4-76.47K
24 Q3-42.3K
24 Q2-45.12K
24 Q1-54.08K
Free Cash Flow Yield
-30%-20%-10%0%med -4.7%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
PRVCF Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-15.59%
Sep 26-12.63%
Sep 26-12.73%
Aug 26-12.89%
Aug 26-15.61%
Aug 26-20.54%
Aug 26-20.89%
Jul 26-20.53%
Jul 26-20.45%
Jul 26-17.89%
Jul 26-21.72%
Jul 26-20.47%
Jun 26-19.42%
Jun 26-23.13%
Jun 26-20.46%
Jun 26-19.41%
May 26-22.72%
May 26-13.09%
May 26-14.73%
May 26-22.44%
May 26-13.78%
Apr 26-14.81%
Apr 26-14.49%
Apr 26-12.74%
Apr 26-15.27%
Mar 26-11.8%
Mar 26-17.24%
Mar 26-17.24%
Mar 26-10.04%
Feb 26-10.45%
Feb 26-9.74%
Feb 26-10.4%
Feb 26-11.11%
Jan 26-11.24%
Jan 26-9.71%
Jan 26-9.59%
Jan 26-9.22%
Jan 26-9.44%
Dec 25-9.8%
Dec 25-5.55%
Dec 25-11.68%
Dec 25-8.96%
Nov 25-5.76%
Nov 25-4.93%
Nov 25-6.01%
Nov 25-5.9%
Oct 25-4.54%
Oct 25-5.42%
Oct 25-5.19%
Oct 25-5.42%
Oct 25-4.85%
Sep 25-3.93%
Sep 25-2.79%
Sep 25-3.3%
Sep 25-3.02%
Aug 25-2.72%
Aug 25-2.46%
Aug 25-2.83%
Aug 25-2.67%
Aug 25-2.83%
Jul 25-3.03%
Jul 25-3.31%
Jul 25-3.02%
Jul 25-2.82%
Jun 25-2.32%
Jun 25-2.11%
Jun 25-2.19%
Jun 25-1.82%
May 25-1.81%
May 25-2.24%
May 25-2.3%
May 25-2.47%
May 25-2.4%
Apr 25-3.2%
Apr 25-2.4%
Apr 25-2.44%
Apr 25-4.22%
Mar 25-3.26%
Mar 25-3.06%
Mar 25-2.82%
Mar 25-2.76%
Feb 25-2.82%
Feb 25-2.68%
Feb 25-2.57%
Feb 25-2.69%
Jan 25-3%
Jan 25-2.8%
Jan 25-2.85%
Jan 25-2.2%
Jan 25-2.81%
Dec 24-2.44%
Dec 24-2.57%
Dec 24-2.45%
Dec 24-2.81%
Nov 24-3.1%
Nov 24-3.16%
Nov 24-3.93%
Nov 24-4.16%
Nov 24-2.97%
Oct 24-4.13%
Price to Sales
02000400060008000med 2707.54Jan 20Feb 20Mar 20Apr 20May 20May 20Jun 20
PRVCF Price to Sales by quarter
PeriodPrice to Sales
Jun 206287.71
Jun 207502.02
Jun 206089.36
Jun 204932.74
May 205007.37
May 203990.01
May 202852.04
May 202923.44
May 202996.44
Apr 202220.54
Apr 202540.79
Apr 202384.7
Apr 201770.84
Mar 201803.49
Mar 201480.46
Mar 202281.13
Mar 202300.64
Feb 202133.23
Feb 202184.08
Feb 202919.14
Feb 203379.28
Jan 203280.55
Jan 203800.62
Jan 202563.05
Jan 202029.84
Jan 202146.04
Price/Operating Cashflow
050100150200250med 69.74Jan 21Feb 21Apr 21May 21Jul 21Aug 21Sep 21
PRVCF Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 2169.92
Sep 2167.79
Sep 2167.7
Sep 2179.3
Aug 2169.74
Aug 2174.46
Aug 2162.28
Aug 2167.68
Jul 2174.13
Jul 2167.36
Jul 2167.63
Jul 2171.22
Jul 2170.88
Jun 21187.08
Jun 21209.59
Jun 21204.35
Jun 21212.22
May 21193.73
May 21191.74
May 21186.75
May 21203.8
Apr 21215.88
Apr 21200.26
Apr 21226.59
Apr 21215.41
Apr 21187.96
Mar 2144.37
Mar 2151.67
Mar 2151.55
Mar 2149.01
Feb 2159.23
Feb 2156.45
Feb 2167.94
Feb 2153.92
Jan 2151.69
Jan 2150.19
Jan 2151.68
Jan 2152.42
Dec 2051.61
PreveCeutical Medical Inc.
PRVCF
Stockpicker

Video analysis: PRVCF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: PRVCF

PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement

newsfilecorp.com · 4 Aug 2026

PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated July 27, 2026, June 12, 2026, May 12, 2026 and April 22, 2026 (the "Prior News Releases"), it has closed a fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement (the "Offering"), which Fourth Tranche consisted of the issuance of 8,600,000 units (each, a "Unit") of the Company at a price of $0.025 per Unit for gross aggregate proceeds of $215,000. The Company closed an initial tranche on May 12, 2026 consisting of the issuance of 13,600,000 Units for gross proceeds of $340,000, a second tranche on June 12, 2026 consisting of the issuance of 9,800,000 Units for gross proceeds of $245,000 and a third tranche on July 27, 2026 consisting of the issuance of 8,000,000 Units for gross proceeds of $200,000.

PreveCeutical Closes Third Tranche of Non-Brokered Private Placement

newsfilecorp.com · 27 Jul 2026

PreveCeutical Closes Third Tranche of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - July 27, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated June 12, 2026, May 12, 2026 and April 22, 2026, it has closed a third tranche (the "Third Tranche") of its previously announced non-brokered private placement (the "Offering"), which Third Tranche consisted of the issuance of 8,000,000 units (each, a "Unit") of the Company at a price of $0.025 per Unit for gross aggregate proceeds of $200,000. The Company closed an initial tranche (the "Initial Tranche") on May 12, 2026 consisting of the issuance of 13,600,000 Units for gross proceeds of $340,000 and a second tranche (the "Second Tranche") on June 12, 2026 consisting of the issuance of 9,800,000 Units for gross proceeds of $245,000.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.